Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
R
R
Guièze
A
A
Renneville
J-M
JM
Cayuela
R B
RB
Abdelali
N
N
Boissel
S
S
de Botton
M-T
MT
Rubio
F
F
Mazingue
E A
EA
Macintyre
M
M
Cheok
F
F
Sigaux
P
P
Fenaux
H
H
Dombret
C
C
Preudhomme
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D005260:Female; D005602:France; D015321:Gene Rearrangement; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
C095514:CBFbeta-MYH11 fusion protein; D015514:Oncogene Proteins, Fusion